The FDA has approved navepegritide (Yuviwel) for the treatment of achondroplasia in children 2 years of age and older[1]. Achondroplasia is the most common form of dwarfism[1]. The drug is administered once a week and belongs to the group of C-type natriuretic peptide (CNP) precursors[1]. The purpose of treatment is to increase linear growth in pediatric patients with achondroplasia who have open epiphyses (bone growth zones)[1]. Approval was issued by the FDA on February 27, 2026[1]. The developer of the drug is Ascendis Pharma[1].